Aktionsplan Indivior PLC
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. weitere details| IPO date | 2014-12-29 |
|---|---|
| ISIN | GB00BN4HT335 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 12.24 |
| Дивиденд ао | 0.475 |
| Сайт | https://www.indivior.com |
| Цена ао | 9.69 |
| Preisänderung pro Tag: | 0% (9.44) |
|---|---|
| Preisänderung pro Woche: | +3.62% (9.11) |
| Preisänderung pro Monat: | -2.48% (9.68) |
| Preisänderung über 3 Monate: | -15.79% (11.21) |
| Preisänderung über sechs Monate: | +15.97% (8.14) |
| Preisänderung pro Jahr: | -51.32% (19.39) |
| Preisänderung über 3 Jahre: | +995.13% (0.862) |
| Preisänderung über 5 Jahre: | +8 805.66% (0.106) |
| Preisänderung seit Jahresbeginn: | -17.98% (11.51) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Two Seas Capital LP | 13670312 | 9.96 |
| Scopia Capital Management LP | 8311367 | 6.06 |
| Vanguard Group Inc | 5846354 | 4.26 |
| Goldman Sachs Group Inc | 5683038 | 4.14 |
| FMR, LLC | 5498087 | 4.01 |
| Artemis Investment Management LLP | 3127399 | 2.28 |
| Bank of America Corporation | 2701855 | 1.97 |
| Polar Capital Holdings PLC | 2621150 | 1.91 |
| Acadian Asset Management. LLC | 2281179 | 1.66 |
| Liontrust Investment Partners LLP | 1995889 | 1.45 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Mark Crossley | CEO & Executive Director | 2.34M | |
| Mr. Ryan Preblick | CFO & Executive Director | 1.14M | |
| Dr. Christian Heidbreder | Chief Scientific Officer | N/A | |
| Mr. Jason Thompson | Vice President of Investor Relations | N/A | |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | N/A | |
| Mr. Jeffrey W. Burris | Chief Legal Officer | N/A | 1972 (53 Jahr) |
| Mr. Jon Fogle | Chief Human Resources Officer | N/A | |
| Mr. Richard Simkin | Chief Commercial Officer | N/A | |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | N/A | |
| Mr. Vishal Kalia | SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer | N/A |
Adresse: United States, North Chesterfield. VA, 10710 Midlothian Turnpike - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.indivior.com
Webseite: https://www.indivior.com
